Eli Lilly reported significant growth in 2025, with total revenue reaching $65.2 billion, a 45% increase from the previous year. The company's GLP-1 drugs, Mounjaro and Zepbound, were major contributors, generating $24.8 billion and $13.5 billion in sales, respectively, marking increases of 99% and 175% year-over-year. In the fourth quarter of 2025, Eli Lilly's revenue was $19.3 billion, reflecting a 43% increase compared to the same quarter in the previous year, driven largely by strong demand for its weight-loss and diabetes drugs. The company also reported adjusted earnings per share of $7.02 for the third quarter, exceeding expectations and prompting an upward revision of its full-year earnings outlook. Additionally, Eli Lilly's market share in the U.S. GLP-1 drug market reached approximately 60%, solidifying its leadership position in this therapeutic area.